Search

Your search keyword '"Haan, M.W. de"' showing total 32 results
Start Over Author "Haan, M.W. de" Publication Type Electronic Resources

Refine your results

32 results on '"Haan, M.W. de"'

1. Safety and long-term effects of renal denervation: Rationale and design of the Dutch registry

Author

Sanders, M.F., Blankestijn, P.J., Voskuil, M., Spiering, W., Vonken, E.J., Rotmans, J.I., Hoeven, B.L. van der, Daemen, J., Meiracker, A.H. van den, Kroon, A.A., Haan, M.W. de, Das, M., Bax, M., Meer, I.M. van der, Overhagen, H. van, Born, B.J. van den, Brussel, P.M. van, Valk, P.H. van der, Gregoor, P.J. Smak, Meuwissen, M., Gomes, M.E.R., Ophuis, T. Oude, Troe, E., Tonino, W.A., Konings, C.J., Vries, P.A. de, Balen, A. van, Heeg, J.E., Smit, J.J., Elvan, A., Steggerda, R., Niamut, S.M., Peels, J.O., Swart, J.B. de, Wardeh, A.J., Groeneveld, J.H., Linden, E. van der, Hemmelder, M.H., Folkeringa, R., Stoel, M.G., Kant, G.D., Herrman, J.P., Wissen, S. van, Deinum, J., Westra, S.W., Aengevaeren, W.R.M., Parlevliet, K.J., Schramm, A., Jessurun, G.A., Rensing, B.J., Winkens, M.H., Wierema, T.K., Santegoets, E., Lipsic, E., Houwerzijl, E., Kater, M., Allaart, C.P., Nap, A., Bots, M.L., Sanders, M.F., Blankestijn, P.J., Voskuil, M., Spiering, W., Vonken, E.J., Rotmans, J.I., Hoeven, B.L. van der, Daemen, J., Meiracker, A.H. van den, Kroon, A.A., Haan, M.W. de, Das, M., Bax, M., Meer, I.M. van der, Overhagen, H. van, Born, B.J. van den, Brussel, P.M. van, Valk, P.H. van der, Gregoor, P.J. Smak, Meuwissen, M., Gomes, M.E.R., Ophuis, T. Oude, Troe, E., Tonino, W.A., Konings, C.J., Vries, P.A. de, Balen, A. van, Heeg, J.E., Smit, J.J., Elvan, A., Steggerda, R., Niamut, S.M., Peels, J.O., Swart, J.B. de, Wardeh, A.J., Groeneveld, J.H., Linden, E. van der, Hemmelder, M.H., Folkeringa, R., Stoel, M.G., Kant, G.D., Herrman, J.P., Wissen, S. van, Deinum, J., Westra, S.W., Aengevaeren, W.R.M., Parlevliet, K.J., Schramm, A., Jessurun, G.A., Rensing, B.J., Winkens, M.H., Wierema, T.K., Santegoets, E., Lipsic, E., Houwerzijl, E., Kater, M., Allaart, C.P., Nap, A., and Bots, M.L. more...

Abstract

Item does not contain fulltext, BACKGROUND: Percutaneous renal denervation (RDN) has recently been introduced as a treatment for therapyresistant hypertension. Also, it has been suggested that RDN may be beneficial for other conditions characterised by increased sympathetic nerve activity. There are still many uncertainties with regard to efficacy, safety, predictors for success and long-term effects. To answer these important questions, we initiated a Dutch RDN registry aiming to collect data from all RDN procedures performed in the Netherlands. METHODS: The Dutch RDN registry is an ongoing investigator-initiated, prospective, multicentre cohort study. Twenty-six Dutch hospitals agreed to participate in this registry. All patients who undergo RDN, regardless of the clinical indication or device that is used, will be included. Data are currently being collected on eligibility and screening, treatment and follow-up. RESULTS: Procedures have been performed since August 2010. At present, data from 306 patients have been entered into the database. The main indication for RDN was hypertension (n = 302, 99%). Patients had a mean office blood pressure of 177/100 (±29/16) mmHg with a median use of three (range 0-8) blood pressure lowering drugs. Mean 24-hour blood pressure before RDN was 157/93 (±18/13) mmHg. RDN was performed with different devices, with the Simplicity™ catheter currently used most frequently. CONCLUSION: Here we report on the rationale and design of the Dutch RDN registry. Enrolment in this investigator-initiated study is ongoing. We present baseline characteristics of the first 306 participants. more...

Published
2016

2. Safety and long-term effects of renal denervation: Rationale and design of the Dutch registry

Author

Sanders, M.F., Blankestijn, P.J., Voskuil, M., Spiering, W., Vonken, E.J., Rotmans, J.I., Hoeven, B.L. van der, Daemen, J., Meiracker, A.H. van den, Kroon, A.A., Haan, M.W. de, Das, M., Bax, M., Meer, I.M. van der, Overhagen, H. van, Born, B.J. van den, Brussel, P.M. van, Valk, P.H. van der, Gregoor, P.J. Smak, Meuwissen, M., Gomes, M.E.R., Ophuis, T. Oude, Troe, E., Tonino, W.A., Konings, C.J., Vries, P.A. de, Balen, A. van, Heeg, J.E., Smit, J.J., Elvan, A., Steggerda, R., Niamut, S.M., Peels, J.O., Swart, J.B. de, Wardeh, A.J., Groeneveld, J.H., Linden, E. van der, Hemmelder, M.H., Folkeringa, R., Stoel, M.G., Kant, G.D., Herrman, J.P., Wissen, S. van, Deinum, J., Westra, S.W., Aengevaeren, W.R.M., Parlevliet, K.J., Schramm, A., Jessurun, G.A., Rensing, B.J., Winkens, M.H., Wierema, T.K., Santegoets, E., Lipsic, E., Houwerzijl, E., Kater, M., Allaart, C.P., Nap, A., Bots, M.L., Sanders, M.F., Blankestijn, P.J., Voskuil, M., Spiering, W., Vonken, E.J., Rotmans, J.I., Hoeven, B.L. van der, Daemen, J., Meiracker, A.H. van den, Kroon, A.A., Haan, M.W. de, Das, M., Bax, M., Meer, I.M. van der, Overhagen, H. van, Born, B.J. van den, Brussel, P.M. van, Valk, P.H. van der, Gregoor, P.J. Smak, Meuwissen, M., Gomes, M.E.R., Ophuis, T. Oude, Troe, E., Tonino, W.A., Konings, C.J., Vries, P.A. de, Balen, A. van, Heeg, J.E., Smit, J.J., Elvan, A., Steggerda, R., Niamut, S.M., Peels, J.O., Swart, J.B. de, Wardeh, A.J., Groeneveld, J.H., Linden, E. van der, Hemmelder, M.H., Folkeringa, R., Stoel, M.G., Kant, G.D., Herrman, J.P., Wissen, S. van, Deinum, J., Westra, S.W., Aengevaeren, W.R.M., Parlevliet, K.J., Schramm, A., Jessurun, G.A., Rensing, B.J., Winkens, M.H., Wierema, T.K., Santegoets, E., Lipsic, E., Houwerzijl, E., Kater, M., Allaart, C.P., Nap, A., and Bots, M.L. more...

Abstract

Item does not contain fulltext, BACKGROUND: Percutaneous renal denervation (RDN) has recently been introduced as a treatment for therapyresistant hypertension. Also, it has been suggested that RDN may be beneficial for other conditions characterised by increased sympathetic nerve activity. There are still many uncertainties with regard to efficacy, safety, predictors for success and long-term effects. To answer these important questions, we initiated a Dutch RDN registry aiming to collect data from all RDN procedures performed in the Netherlands. METHODS: The Dutch RDN registry is an ongoing investigator-initiated, prospective, multicentre cohort study. Twenty-six Dutch hospitals agreed to participate in this registry. All patients who undergo RDN, regardless of the clinical indication or device that is used, will be included. Data are currently being collected on eligibility and screening, treatment and follow-up. RESULTS: Procedures have been performed since August 2010. At present, data from 306 patients have been entered into the database. The main indication for RDN was hypertension (n = 302, 99%). Patients had a mean office blood pressure of 177/100 (±29/16) mmHg with a median use of three (range 0-8) blood pressure lowering drugs. Mean 24-hour blood pressure before RDN was 157/93 (±18/13) mmHg. RDN was performed with different devices, with the Simplicity™ catheter currently used most frequently. CONCLUSION: Here we report on the rationale and design of the Dutch RDN registry. Enrolment in this investigator-initiated study is ongoing. We present baseline characteristics of the first 306 participants. more...

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results

3. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.

Author

Bax, L., Woittiez, A.J.J., Kouwenberg, H.J., Mali, W.P.Th., Buskens, E., Beek, F.J., Braam, B., Huysmans, F.T.M., Schultze Kool, L.J., Rutten, M.J.C.M., Doorenbos, C.J., Aarts, J.C., Rabelink, T.J., Plouin, P.F., Raynaud, A., Montfrans, G.A. van, Reekers, J.A., Meiracker, A.H. van den, Pattynama, P.M., Ven, P.J. van der, Vroegindeweij, D., Kroon, A.A., Haan, M.W. de, Postma, C.T., Beutler, J.J., Bax, L., Woittiez, A.J.J., Kouwenberg, H.J., Mali, W.P.Th., Buskens, E., Beek, F.J., Braam, B., Huysmans, F.T.M., Schultze Kool, L.J., Rutten, M.J.C.M., Doorenbos, C.J., Aarts, J.C., Rabelink, T.J., Plouin, P.F., Raynaud, A., Montfrans, G.A. van, Reekers, J.A., Meiracker, A.H. van den, Pattynama, P.M., Ven, P.J. van der, Vroegindeweij, D., Kroon, A.A., Haan, M.W. de, Postma, C.T., and Beutler, J.J. more...

Abstract

Contains fulltext : 81485.pdf (publisher's version ) (Closed access), BACKGROUND: Little is known about the efficacy and safety of renal artery stenting in patients with atherosclerotic renal artery stenosis (ARAS) and impaired renal function. OBJECTIVE: To determine the efficacy and safety of stent placement in patients with ARAS and impaired renal function. DESIGN: Randomized clinical trial. Randomization was centralized and computer generated, and allocation was assigned by e-mail. Patients, providers, and persons who assessed outcomes were not blinded to treatment assignment. SETTING: 10 European medical centers. PARTICIPANTS: 140 patients with creatinine clearance less than 80 mL/min per 1.73 m(2) and ARAS of 50% or greater. INTERVENTION: Stent placement and medical treatment (64 patients) or medical treatment only (76 patients). Medical treatment consisted of antihypertensive treatment, a statin, and aspirin. MEASUREMENTS: The primary end point was a 20% or greater decrease in creatinine clearance. Secondary end points included safety and cardiovascular morbidity and mortality. RESULTS: Forty-six of 64 patients assigned to stent placement had the procedure. Ten of the 64 patients (16%) in the stent placement group and 16 patients (22%) in the medication group reached the primary end point (hazard ratio, 0.73 [95% CI, 0.33 to 1.61]). Serious complications occurred in the stent group, including 2 procedure-related deaths (3%), 1 late death secondary to an infected hematoma, and 1 patient who required dialysis secondary to cholesterol embolism. The groups did not differ for other secondary end points. LIMITATION: Many patients were falsely identified as having renal artery stenosis greater than 50% by noninvasive imaging and did not ultimately require stenting. CONCLUSION: Stent placement with medical treatment had no clear effect on progression of impaired renal function but led to a small number of significant procedure-related complications. The study findings favor a conservative approach to patients with ARAS, focused on cardi more...

Published
2009

4. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.

Author

Bax, L., Woittiez, A.J.J., Kouwenberg, H.J., Mali, W.P.Th., Buskens, E., Beek, F.J., Braam, B., Huysmans, F.T.M., Schultze Kool, L.J., Rutten, M.J.C.M., Doorenbos, C.J., Aarts, J.C., Rabelink, T.J., Plouin, P.F., Raynaud, A., Montfrans, G.A. van, Reekers, J.A., Meiracker, A.H. van den, Pattynama, P.M., Ven, P.J. van der, Vroegindeweij, D., Kroon, A.A., Haan, M.W. de, Postma, C.T., Beutler, J.J., Bax, L., Woittiez, A.J.J., Kouwenberg, H.J., Mali, W.P.Th., Buskens, E., Beek, F.J., Braam, B., Huysmans, F.T.M., Schultze Kool, L.J., Rutten, M.J.C.M., Doorenbos, C.J., Aarts, J.C., Rabelink, T.J., Plouin, P.F., Raynaud, A., Montfrans, G.A. van, Reekers, J.A., Meiracker, A.H. van den, Pattynama, P.M., Ven, P.J. van der, Vroegindeweij, D., Kroon, A.A., Haan, M.W. de, Postma, C.T., and Beutler, J.J. more...

Abstract

Contains fulltext : 81485.pdf (publisher's version ) (Closed access), BACKGROUND: Little is known about the efficacy and safety of renal artery stenting in patients with atherosclerotic renal artery stenosis (ARAS) and impaired renal function. OBJECTIVE: To determine the efficacy and safety of stent placement in patients with ARAS and impaired renal function. DESIGN: Randomized clinical trial. Randomization was centralized and computer generated, and allocation was assigned by e-mail. Patients, providers, and persons who assessed outcomes were not blinded to treatment assignment. SETTING: 10 European medical centers. PARTICIPANTS: 140 patients with creatinine clearance less than 80 mL/min per 1.73 m(2) and ARAS of 50% or greater. INTERVENTION: Stent placement and medical treatment (64 patients) or medical treatment only (76 patients). Medical treatment consisted of antihypertensive treatment, a statin, and aspirin. MEASUREMENTS: The primary end point was a 20% or greater decrease in creatinine clearance. Secondary end points included safety and cardiovascular morbidity and mortality. RESULTS: Forty-six of 64 patients assigned to stent placement had the procedure. Ten of the 64 patients (16%) in the stent placement group and 16 patients (22%) in the medication group reached the primary end point (hazard ratio, 0.73 [95% CI, 0.33 to 1.61]). Serious complications occurred in the stent group, including 2 procedure-related deaths (3%), 1 late death secondary to an infected hematoma, and 1 patient who required dialysis secondary to cholesterol embolism. The groups did not differ for other secondary end points. LIMITATION: Many patients were falsely identified as having renal artery stenosis greater than 50% by noninvasive imaging and did not ultimately require stenting. CONCLUSION: Stent placement with medical treatment had no clear effect on progression of impaired renal function but led to a small number of significant procedure-related complications. The study findings favor a conservative approach to patients with ARAS, focused on cardi more...

Published
2009

5. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.

Author

Bax, L., Woittiez, A.J.J., Kouwenberg, H.J., Mali, W.P.Th., Buskens, E., Beek, F.J., Braam, B., Huysmans, F.T.M., Schultze Kool, L.J., Rutten, M.J.C.M., Doorenbos, C.J., Aarts, J.C., Rabelink, T.J., Plouin, P.F., Raynaud, A., Montfrans, G.A. van, Reekers, J.A., Meiracker, A.H. van den, Pattynama, P.M., Ven, P.J. van der, Vroegindeweij, D., Kroon, A.A., Haan, M.W. de, Postma, C.T., Beutler, J.J., Bax, L., Woittiez, A.J.J., Kouwenberg, H.J., Mali, W.P.Th., Buskens, E., Beek, F.J., Braam, B., Huysmans, F.T.M., Schultze Kool, L.J., Rutten, M.J.C.M., Doorenbos, C.J., Aarts, J.C., Rabelink, T.J., Plouin, P.F., Raynaud, A., Montfrans, G.A. van, Reekers, J.A., Meiracker, A.H. van den, Pattynama, P.M., Ven, P.J. van der, Vroegindeweij, D., Kroon, A.A., Haan, M.W. de, Postma, C.T., and Beutler, J.J. more...

Abstract

Contains fulltext : 81485.pdf (publisher's version ) (Closed access), BACKGROUND: Little is known about the efficacy and safety of renal artery stenting in patients with atherosclerotic renal artery stenosis (ARAS) and impaired renal function. OBJECTIVE: To determine the efficacy and safety of stent placement in patients with ARAS and impaired renal function. DESIGN: Randomized clinical trial. Randomization was centralized and computer generated, and allocation was assigned by e-mail. Patients, providers, and persons who assessed outcomes were not blinded to treatment assignment. SETTING: 10 European medical centers. PARTICIPANTS: 140 patients with creatinine clearance less than 80 mL/min per 1.73 m(2) and ARAS of 50% or greater. INTERVENTION: Stent placement and medical treatment (64 patients) or medical treatment only (76 patients). Medical treatment consisted of antihypertensive treatment, a statin, and aspirin. MEASUREMENTS: The primary end point was a 20% or greater decrease in creatinine clearance. Secondary end points included safety and cardiovascular morbidity and mortality. RESULTS: Forty-six of 64 patients assigned to stent placement had the procedure. Ten of the 64 patients (16%) in the stent placement group and 16 patients (22%) in the medication group reached the primary end point (hazard ratio, 0.73 [95% CI, 0.33 to 1.61]). Serious complications occurred in the stent group, including 2 procedure-related deaths (3%), 1 late death secondary to an infected hematoma, and 1 patient who required dialysis secondary to cholesterol embolism. The groups did not differ for other secondary end points. LIMITATION: Many patients were falsely identified as having renal artery stenosis greater than 50% by noninvasive imaging and did not ultimately require stenting. CONCLUSION: Stent placement with medical treatment had no clear effect on progression of impaired renal function but led to a small number of significant procedure-related complications. The study findings favor a conservative approach to patients with ARAS, focused on cardi more...

Published
2009

6. Peripheral artery disease: clinical and cost comparison between duplex ultrasonography and contrast-enhanced magnetic resonance angiography—a multicenter randomized trial.

Author

Vries, M. de, Ouwendijk, R., Flobbe, K., Nelemans, P.J., Kessels, A.G.H., Schurink, G.W., Vliet, J.A. van der, Cuypers, P.W., Duijm, L.E.M., Engelshoven, J.M. van, Hunink, M.G.M., Haan, M.W. de, Vries, M. de, Ouwendijk, R., Flobbe, K., Nelemans, P.J., Kessels, A.G.H., Schurink, G.W., Vliet, J.A. van der, Cuypers, P.W., Duijm, L.E.M., Engelshoven, J.M. van, Hunink, M.G.M., and Haan, M.W. de more...

Abstract

Contains fulltext : 51529.pdf (publisher's version ) (Closed access)

Published
2007

7. Peripheral artery disease: clinical and cost comparison between duplex ultrasonography and contrast-enhanced magnetic resonance angiography—a multicenter randomized trial.

Author

Vries, M. de, Ouwendijk, R., Flobbe, K., Nelemans, P.J., Kessels, A.G.H., Schurink, G.W., Vliet, J.A. van der, Cuypers, P.W., Duijm, L.E.M., Engelshoven, J.M. van, Hunink, M.G.M., Haan, M.W. de, Vries, M. de, Ouwendijk, R., Flobbe, K., Nelemans, P.J., Kessels, A.G.H., Schurink, G.W., Vliet, J.A. van der, Cuypers, P.W., Duijm, L.E.M., Engelshoven, J.M. van, Hunink, M.G.M., and Haan, M.W. de more...

Abstract

Contains fulltext : 51529.pdf (publisher's version ) (Closed access)

Published
2007

8. Peripheral artery disease: clinical and cost comparison between duplex ultrasonography and contrast-enhanced magnetic resonance angiography—a multicenter randomized trial.

Author

Vries, M. de, Ouwendijk, R., Flobbe, K., Nelemans, P.J., Kessels, A.G.H., Schurink, G.W., Vliet, J.A. van der, Cuypers, P.W., Duijm, L.E.M., Engelshoven, J.M. van, Hunink, M.G.M., Haan, M.W. de, Vries, M. de, Ouwendijk, R., Flobbe, K., Nelemans, P.J., Kessels, A.G.H., Schurink, G.W., Vliet, J.A. van der, Cuypers, P.W., Duijm, L.E.M., Engelshoven, J.M. van, Hunink, M.G.M., and Haan, M.W. de more...

Abstract

Contains fulltext : 51529.pdf (publisher's version ) (Closed access)

Published
2007

9. Peripheral arterial disease: clinical and cost comparisons between duplex US and contrast-enhanced MR angiography--a multicenter randomized trial.

Author

Vries, M. de, Ouwendijk, R., Flobbe, K., Nelemans, P.J., Kessels, A.G.H., Schurink, G.H., Vliet, J.A. van der, Heijstraten, F.M.J., Cuypers, P.W., Duijm, L.E.M., Engelshoven, J.M. van, Hunink, M.G.M., Haan, M.W. de, Vries, M. de, Ouwendijk, R., Flobbe, K., Nelemans, P.J., Kessels, A.G.H., Schurink, G.H., Vliet, J.A. van der, Heijstraten, F.M.J., Cuypers, P.W., Duijm, L.E.M., Engelshoven, J.M. van, Hunink, M.G.M., and Haan, M.W. de more...

Abstract

Contains fulltext : 49785_pub.pdf (publisher's version ) (Closed access), PURPOSE: To prospectively determine the clinical and economic consequences of replacing duplex ultrasonography (US) with contrast material-enhanced magnetic resonance (MR) angiography for the initial imaging work-up of patients with peripheral arterial disease (PAD). MATERIALS AND METHODS: This randomized multicenter study was approved by the institutional review board of each hospital, and all patients signed written informed consent prior to randomization. Patients with PAD who needed to undergo imaging work-up and who had an ankle-brachial pressure index (ABPI) of less than 0.90 were recruited by vascular surgeons between January 2002 and September 2003. Patients were randomly assigned to undergo contrast-enhanced MR angiography or duplex US. The primary outcome measure was cost. Secondary outcome measures included therapeutic confidence, changes in disease severity, and changes in quality of life (QOL) assessed during 6 months of follow-up. Indicators for disease severity were based on the Rutherford classification, treadmill walking distance, ABPI at rest, and ABPI after exercise. QOL was assessed with the Rating Scale, Short Form 36, EuroQol-5D, and VascuQol questionnaires. The cost of (additional) imaging procedures, therapeutic interventions, and outpatient visits were calculated from a hospital perspective (ie, all costs incurred inside the hospital were estimated, including physician costs). Data were evaluated by using the Student t test and a multivariable linear regression analysis. RESULTS: At 6 months, 352 patients (239 [68%] men, 113 [32%] women; mean age, 65 years) were analyzed. The use of contrast-enhanced MR angiography versus duplex US reduced the number of additional vascular imaging procedures by 42%; contrast-enhanced MR angiography was also associated with higher therapeutic confidence. Diagnostic costs for contrast-enhanced MR angiography were 167 euros (186 dollars) higher than those for duplex US (P < .001). No statistically significant d more...

Published
2006

10. Peripheral arterial disease: clinical and cost comparisons between duplex US and contrast-enhanced MR angiography--a multicenter randomized trial.

Author

Vries, M. de, Ouwendijk, R., Flobbe, K., Nelemans, P.J., Kessels, A.G.H., Schurink, G.H., Vliet, J.A. van der, Heijstraten, F.M.J., Cuypers, P.W., Duijm, L.E.M., Engelshoven, J.M. van, Hunink, M.G.M., Haan, M.W. de, Vries, M. de, Ouwendijk, R., Flobbe, K., Nelemans, P.J., Kessels, A.G.H., Schurink, G.H., Vliet, J.A. van der, Heijstraten, F.M.J., Cuypers, P.W., Duijm, L.E.M., Engelshoven, J.M. van, Hunink, M.G.M., and Haan, M.W. de more...

Abstract

Contains fulltext : 49785_pub.pdf (publisher's version ) (Closed access), PURPOSE: To prospectively determine the clinical and economic consequences of replacing duplex ultrasonography (US) with contrast material-enhanced magnetic resonance (MR) angiography for the initial imaging work-up of patients with peripheral arterial disease (PAD). MATERIALS AND METHODS: This randomized multicenter study was approved by the institutional review board of each hospital, and all patients signed written informed consent prior to randomization. Patients with PAD who needed to undergo imaging work-up and who had an ankle-brachial pressure index (ABPI) of less than 0.90 were recruited by vascular surgeons between January 2002 and September 2003. Patients were randomly assigned to undergo contrast-enhanced MR angiography or duplex US. The primary outcome measure was cost. Secondary outcome measures included therapeutic confidence, changes in disease severity, and changes in quality of life (QOL) assessed during 6 months of follow-up. Indicators for disease severity were based on the Rutherford classification, treadmill walking distance, ABPI at rest, and ABPI after exercise. QOL was assessed with the Rating Scale, Short Form 36, EuroQol-5D, and VascuQol questionnaires. The cost of (additional) imaging procedures, therapeutic interventions, and outpatient visits were calculated from a hospital perspective (ie, all costs incurred inside the hospital were estimated, including physician costs). Data were evaluated by using the Student t test and a multivariable linear regression analysis. RESULTS: At 6 months, 352 patients (239 [68%] men, 113 [32%] women; mean age, 65 years) were analyzed. The use of contrast-enhanced MR angiography versus duplex US reduced the number of additional vascular imaging procedures by 42%; contrast-enhanced MR angiography was also associated with higher therapeutic confidence. Diagnostic costs for contrast-enhanced MR angiography were 167 euros (186 dollars) higher than those for duplex US (P < .001). No statistically significant d more...

Published
2006

11. Peripheral arterial disease: clinical and cost comparisons between duplex US and contrast-enhanced MR angiography--a multicenter randomized trial.

Author

Vries, M. de, Ouwendijk, R., Flobbe, K., Nelemans, P.J., Kessels, A.G.H., Schurink, G.H., Vliet, J.A. van der, Heijstraten, F.M.J., Cuypers, P.W., Duijm, L.E.M., Engelshoven, J.M. van, Hunink, M.G.M., Haan, M.W. de, Vries, M. de, Ouwendijk, R., Flobbe, K., Nelemans, P.J., Kessels, A.G.H., Schurink, G.H., Vliet, J.A. van der, Heijstraten, F.M.J., Cuypers, P.W., Duijm, L.E.M., Engelshoven, J.M. van, Hunink, M.G.M., and Haan, M.W. de more...

Abstract

Contains fulltext : 49785_pub.pdf (publisher's version ) (Closed access), PURPOSE: To prospectively determine the clinical and economic consequences of replacing duplex ultrasonography (US) with contrast material-enhanced magnetic resonance (MR) angiography for the initial imaging work-up of patients with peripheral arterial disease (PAD). MATERIALS AND METHODS: This randomized multicenter study was approved by the institutional review board of each hospital, and all patients signed written informed consent prior to randomization. Patients with PAD who needed to undergo imaging work-up and who had an ankle-brachial pressure index (ABPI) of less than 0.90 were recruited by vascular surgeons between January 2002 and September 2003. Patients were randomly assigned to undergo contrast-enhanced MR angiography or duplex US. The primary outcome measure was cost. Secondary outcome measures included therapeutic confidence, changes in disease severity, and changes in quality of life (QOL) assessed during 6 months of follow-up. Indicators for disease severity were based on the Rutherford classification, treadmill walking distance, ABPI at rest, and ABPI after exercise. QOL was assessed with the Rating Scale, Short Form 36, EuroQol-5D, and VascuQol questionnaires. The cost of (additional) imaging procedures, therapeutic interventions, and outpatient visits were calculated from a hospital perspective (ie, all costs incurred inside the hospital were estimated, including physician costs). Data were evaluated by using the Student t test and a multivariable linear regression analysis. RESULTS: At 6 months, 352 patients (239 [68%] men, 113 [32%] women; mean age, 65 years) were analyzed. The use of contrast-enhanced MR angiography versus duplex US reduced the number of additional vascular imaging procedures by 42%; contrast-enhanced MR angiography was also associated with higher therapeutic confidence. Diagnostic costs for contrast-enhanced MR angiography were 167 euros (186 dollars) higher than those for duplex US (P < .001). No statistically significant d more...

Published
2006

12. Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis.

Author

Vasbinder, G.B., Nelemans, P.J., Kessels, A.G.H., Kroon, A.A., Maki, J.H., Leiner, T., Beek, F.J.A., Korst, M., Flobbe, K., Haan, M.W. de, Zwam, W.H. van, Postma, C.T., Hunink, M.G.M., Leeuw, P.W. de, Engelshoven, J. van, Vasbinder, G.B., Nelemans, P.J., Kessels, A.G.H., Kroon, A.A., Maki, J.H., Leiner, T., Beek, F.J.A., Korst, M., Flobbe, K., Haan, M.W. de, Zwam, W.H. van, Postma, C.T., Hunink, M.G.M., Leeuw, P.W. de, and Engelshoven, J. van more...

Abstract

Item does not contain fulltext

Published
2004

13. Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis.

Author

Vasbinder, G.B., Nelemans, P.J., Kessels, A.G.H., Kroon, A.A., Maki, J.H., Leiner, T., Beek, F.J.A., Korst, M., Flobbe, K., Haan, M.W. de, Zwam, W.H. van, Postma, C.T., Hunink, M.G.M., Leeuw, P.W. de, Engelshoven, J. van, Vasbinder, G.B., Nelemans, P.J., Kessels, A.G.H., Kroon, A.A., Maki, J.H., Leiner, T., Beek, F.J.A., Korst, M., Flobbe, K., Haan, M.W. de, Zwam, W.H. van, Postma, C.T., Hunink, M.G.M., Leeuw, P.W. de, and Engelshoven, J. van more...

Abstract

Item does not contain fulltext

Published
2004

14. NHG-Standaard Depressieve stoornis (depressie).

Author

Marwijk, H.W.J. van, Grundmeijer, H.G.L.M., Bijl, D., Gelderen, M.G. van, Haan, M.W. de, Weel-Baumgarten, E.M. van, Burgers, J.S., Boukes, F.S., Romeijnders, A., Marwijk, H.W.J. van, Grundmeijer, H.G.L.M., Bijl, D., Gelderen, M.G. van, Haan, M.W. de, Weel-Baumgarten, E.M. van, Burgers, J.S., Boukes, F.S., and Romeijnders, A. more...

Abstract

Item does not contain fulltext

Published
2003

15. The benefit of stent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by atherosclerotic ostial stenosis of the renal artery. The STAR-study: rationale and study design.

Author

Bax, L., Mali, W.P.Th., Buskens, E., Koomans, H.A., Beutler, J.J., Braam, B., Beek, F.J.A., Rabelink, T.J., Postma, C.T., Huysmans, F.T.M., Deinum, J., Thien, Th., Schultze Kool, L.J., Woittiez, A.J.J., Kouwenberg, J.J., Meiracker, A.H. van den, Pattynama, P.M., Ven, P.J. van der, Vroegindeweij, D., Doorenbos, C.J., Aarts, J., Kroon, A.A., Leeuw, P.W. de, Haan, M.W. de, Engelshoven, J. van, Rutten, M.J.C.M., Montfrans, G.A. van, Reekers, J.A., Plouin, P.F., Batide Alanore, A. La, Azizi, M., Raynaud, A., Harden, P.N., Cowling, M., Bax, L., Mali, W.P.Th., Buskens, E., Koomans, H.A., Beutler, J.J., Braam, B., Beek, F.J.A., Rabelink, T.J., Postma, C.T., Huysmans, F.T.M., Deinum, J., Thien, Th., Schultze Kool, L.J., Woittiez, A.J.J., Kouwenberg, J.J., Meiracker, A.H. van den, Pattynama, P.M., Ven, P.J. van der, Vroegindeweij, D., Doorenbos, C.J., Aarts, J., Kroon, A.A., Leeuw, P.W. de, Haan, M.W. de, Engelshoven, J. van, Rutten, M.J.C.M., Montfrans, G.A. van, Reekers, J.A., Plouin, P.F., Batide Alanore, A. La, Azizi, M., Raynaud, A., Harden, P.N., and Cowling, M. more...

Abstract

Item does not contain fulltext, BACKGROUND: Atherosclerotic renal artery stenosis (ARAS) is associated with progressive loss of renal function and is one of the most important causes of renal failure in the elderly. Current treatment includes restoration of the renal arterial lumen by endovascular stent placement. However, this treatment only affects damage caused by ARAS due to the stenosis and ensuing post-stenotic ischemia. ARAS patients have severe general vascular disease. Atherosclerosis and hypertension can also damage the kidney parenchyma causing renal failure. Medical treatment focuses on the latter. Lipid-lowering drugs (statins) could reduce renal failure progression and could reduce the overall high cardiovascular risk. The additional effect on preserving renal function of stent placement as compared to medical therapy alone is unknown. Therefore, the STAR-study aims to compare the effects of renal artery stent placement together with medication vs. medication alone on renal function in ARAS patients. METHOD: Patients with an ARAS of > or = 50% and renal failure (creatinine (Cr) clearance < 80 mL/min/1.73 m2) are randomly assigned to stent placement with medication or to medication alone. Medication consists of statins, anti-hypertensive drugs and antiplatelet therapy. Patients are followed for 2 yrs with extended follow-up to 5 yrs. The primary outcome of this study is a reduction in Cr clearance > 20% compared to baseline. This trial will include 140 patients. more...

Published
2003

16. NHG-Standaard Depressieve stoornis (depressie).

Author

Marwijk, H.W.J. van, Grundmeijer, H.G.L.M., Bijl, D., Gelderen, M.G. van, Haan, M.W. de, Weel-Baumgarten, E.M. van, Burgers, J.S., Boukes, F.S., Romeijnders, A., Marwijk, H.W.J. van, Grundmeijer, H.G.L.M., Bijl, D., Gelderen, M.G. van, Haan, M.W. de, Weel-Baumgarten, E.M. van, Burgers, J.S., Boukes, F.S., and Romeijnders, A. more...

Abstract

Item does not contain fulltext

Published
2003

17. The benefit of stent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by atherosclerotic ostial stenosis of the renal artery. The STAR-study: rationale and study design.

Author

Bax, L., Mali, W.P.Th., Buskens, E., Koomans, H.A., Beutler, J.J., Braam, B., Beek, F.J.A., Rabelink, T.J., Postma, C.T., Huysmans, F.T.M., Deinum, J., Thien, Th., Schultze Kool, L.J., Woittiez, A.J.J., Kouwenberg, J.J., Meiracker, A.H. van den, Pattynama, P.M., Ven, P.J. van der, Vroegindeweij, D., Doorenbos, C.J., Aarts, J., Kroon, A.A., Leeuw, P.W. de, Haan, M.W. de, Engelshoven, J. van, Rutten, M.J.C.M., Montfrans, G.A. van, Reekers, J.A., Plouin, P.F., Batide Alanore, A. La, Azizi, M., Raynaud, A., Harden, P.N., Cowling, M., Bax, L., Mali, W.P.Th., Buskens, E., Koomans, H.A., Beutler, J.J., Braam, B., Beek, F.J.A., Rabelink, T.J., Postma, C.T., Huysmans, F.T.M., Deinum, J., Thien, Th., Schultze Kool, L.J., Woittiez, A.J.J., Kouwenberg, J.J., Meiracker, A.H. van den, Pattynama, P.M., Ven, P.J. van der, Vroegindeweij, D., Doorenbos, C.J., Aarts, J., Kroon, A.A., Leeuw, P.W. de, Haan, M.W. de, Engelshoven, J. van, Rutten, M.J.C.M., Montfrans, G.A. van, Reekers, J.A., Plouin, P.F., Batide Alanore, A. La, Azizi, M., Raynaud, A., Harden, P.N., and Cowling, M. more...

Abstract

Item does not contain fulltext, BACKGROUND: Atherosclerotic renal artery stenosis (ARAS) is associated with progressive loss of renal function and is one of the most important causes of renal failure in the elderly. Current treatment includes restoration of the renal arterial lumen by endovascular stent placement. However, this treatment only affects damage caused by ARAS due to the stenosis and ensuing post-stenotic ischemia. ARAS patients have severe general vascular disease. Atherosclerosis and hypertension can also damage the kidney parenchyma causing renal failure. Medical treatment focuses on the latter. Lipid-lowering drugs (statins) could reduce renal failure progression and could reduce the overall high cardiovascular risk. The additional effect on preserving renal function of stent placement as compared to medical therapy alone is unknown. Therefore, the STAR-study aims to compare the effects of renal artery stent placement together with medication vs. medication alone on renal function in ARAS patients. METHOD: Patients with an ARAS of > or = 50% and renal failure (creatinine (Cr) clearance < 80 mL/min/1.73 m2) are randomly assigned to stent placement with medication or to medication alone. Medication consists of statins, anti-hypertensive drugs and antiplatelet therapy. Patients are followed for 2 yrs with extended follow-up to 5 yrs. The primary outcome of this study is a reduction in Cr clearance > 20% compared to baseline. This trial will include 140 patients. more...

Published
2003

18. The benefit of stent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by atherosclerotic ostial stenosis of the renal artery. The STAR-study: rationale and study design.

Author

Bax, L., Mali, W.P.Th., Buskens, E., Koomans, H.A., Beutler, J.J., Braam, B., Beek, F.J.A., Rabelink, T.J., Postma, C.T., Huysmans, F.T.M., Deinum, J., Thien, Th., Schultze Kool, L.J., Woittiez, A.J.J., Kouwenberg, J.J., Meiracker, A.H. van den, Pattynama, P.M., Ven, P.J. van der, Vroegindeweij, D., Doorenbos, C.J., Aarts, J., Kroon, A.A., Leeuw, P.W. de, Haan, M.W. de, Engelshoven, J. van, Rutten, M.J.C.M., Montfrans, G.A. van, Reekers, J.A., Plouin, P.F., Batide Alanore, A. La, Azizi, M., Raynaud, A., Harden, P.N., Cowling, M., Bax, L., Mali, W.P.Th., Buskens, E., Koomans, H.A., Beutler, J.J., Braam, B., Beek, F.J.A., Rabelink, T.J., Postma, C.T., Huysmans, F.T.M., Deinum, J., Thien, Th., Schultze Kool, L.J., Woittiez, A.J.J., Kouwenberg, J.J., Meiracker, A.H. van den, Pattynama, P.M., Ven, P.J. van der, Vroegindeweij, D., Doorenbos, C.J., Aarts, J., Kroon, A.A., Leeuw, P.W. de, Haan, M.W. de, Engelshoven, J. van, Rutten, M.J.C.M., Montfrans, G.A. van, Reekers, J.A., Plouin, P.F., Batide Alanore, A. La, Azizi, M., Raynaud, A., Harden, P.N., and Cowling, M. more...

Abstract

Item does not contain fulltext, BACKGROUND: Atherosclerotic renal artery stenosis (ARAS) is associated with progressive loss of renal function and is one of the most important causes of renal failure in the elderly. Current treatment includes restoration of the renal arterial lumen by endovascular stent placement. However, this treatment only affects damage caused by ARAS due to the stenosis and ensuing post-stenotic ischemia. ARAS patients have severe general vascular disease. Atherosclerosis and hypertension can also damage the kidney parenchyma causing renal failure. Medical treatment focuses on the latter. Lipid-lowering drugs (statins) could reduce renal failure progression and could reduce the overall high cardiovascular risk. The additional effect on preserving renal function of stent placement as compared to medical therapy alone is unknown. Therefore, the STAR-study aims to compare the effects of renal artery stent placement together with medication vs. medication alone on renal function in ARAS patients. METHOD: Patients with an ARAS of > or = 50% and renal failure (creatinine (Cr) clearance < 80 mL/min/1.73 m2) are randomly assigned to stent placement with medication or to medication alone. Medication consists of statins, anti-hypertensive drugs and antiplatelet therapy. Patients are followed for 2 yrs with extended follow-up to 5 yrs. The primary outcome of this study is a reduction in Cr clearance > 20% compared to baseline. This trial will include 140 patients. more...

Published
2003

19. NHG-Standaard Depressieve stoornis (depressie).

Author

Marwijk, H.W.J. van, Grundmeijer, H.G.L.M., Bijl, D., Gelderen, M.G. van, Haan, M.W. de, Weel-Baumgarten, E.M. van, Burgers, J.S., Boukes, F.S., Romeijnders, A., Marwijk, H.W.J. van, Grundmeijer, H.G.L.M., Bijl, D., Gelderen, M.G. van, Haan, M.W. de, Weel-Baumgarten, E.M. van, Burgers, J.S., Boukes, F.S., and Romeijnders, A. more...

Abstract

Item does not contain fulltext

Published
2003

26. Managing imminent miscarriage in primary health care

Author

Haan, M.W. de, Grol, R.P.T.M., Wijkel, D., Fleuren, M., Haan, M.W. de, Grol, R.P.T.M., Wijkel, D., and Fleuren, M.

Abstract

VU, 21 november 1997, Promotores : Haan, M.W. de, Grol, R.P.T.M., Wijkel, D., Item does not contain fulltext

Published
1997

28. Managing imminent miscarriage in primary health care

Author

Haan, M.W. de, Grol, R.P.T.M., Wijkel, D., Fleuren, M., Haan, M.W. de, Grol, R.P.T.M., Wijkel, D., and Fleuren, M.

Abstract

VU, 21 november 1997, Promotores : Haan, M.W. de, Grol, R.P.T.M., Wijkel, D., Item does not contain fulltext

Published
1997

31. Managing imminent miscarriage in primary health care

Author

Haan, M.W. de, Grol, R.P.T.M., Wijkel, D., Fleuren, M., Haan, M.W. de, Grol, R.P.T.M., Wijkel, D., and Fleuren, M.

Abstract

VU, 21 november 1997, Promotores : Haan, M.W. de, Grol, R.P.T.M., Wijkel, D., Item does not contain fulltext

Published
1997